Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX +/- Trastuzumab in Advanced Gastric and Esophageal Cancer
NCT01928290Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2013
- Primary completion
- Dec 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, oxaliplatin, folinic acid, fluorouracil, trastuzumab in gastric cancer (GC), esophageal cancer, gastroesophageal junction cancer, sponsored by Washington University School of Medicine. Started Nov 2013; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01928290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01928290.